Zobrazeno 1 - 10
of 25
pro vyhledávání: ''
Autor:
Shisheng Tan, Sanjun Cai, Ji Zhu, Zhen Zhang, Yaqun Zhu, Hongyan Zhang, Xin Wang, Chen Zhang, Tao Zhang, Jianhui Jia, Jialin Yang, Xinchen Sun, Hui Zhang, Wei Zhang, F. Xia, Juefeng Wan, Yuanyuan Zhao, Anwen Liu, Junxin Wu, Luying Liu, Juying Zhou, Lijun Shen, Gang Cai
Publikováno v:
Journal of Clinical Oncology
PURPOSE Differentiating the irinotecan dose on the basis of the uridine diphosphate glucuronosyltransferase 1A1 ( UGT1A1) genotype improves the pathologic complete response (pCR) rate. In this study, we further investigated preoperative irinotecan co
Autor:
Yunhai Li, Kuaile Zhao, Chaoyang Wu, Yun Chen, Saiquan Lu, Jiancheng Li, Zhengfei Zhu, Huarong Tang, Min Fan, Huixun Jia, Jinjun Ye, Ling Li, Jialiang Zhou, Yi Xia, Weixin Zhao, Zhen Zhang, Qin Lin
Publikováno v:
Journal of Clinical Oncology
PURPOSE This trial aimed to assess the efficacy and safety of the paclitaxel plus fluorouracil regimen versus the cisplatin plus fluorouracil regimen in definitive concurrent chemoradiotherapy (dCRT) in patients with locally advanced esophageal squam
Autor:
Takayuki Yoshino, Ashwin Gollerkeri, Tormod Kyrre Guren, K. Maharry, Hendrik Tobias Arkenau, Fortunato Ciardiello, Neeltje Steeghs, Pilar García-Alfonso, Josep Tabernero, Eric Van Cutsem, Jayesh Desai, Scott Kopetz, Fotios Loupakis, Janna Christy-Bittel, Rona Yaeger, Elena Elez, Yong Sang Hong, Harpreet Wasan, Axel Grothey
Publikováno v:
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology
PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAFV600E–mutant metastatic colorectal cancer (mCRC), after progression on 1-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b794b16b7cce9f9668d73f1cac67945d
https://hdl.handle.net/11351/6118
https://hdl.handle.net/11351/6118
Autor:
Inge Ludwig, Ellen van der Spek, Paul A F Geerts, Pieter Sonneveld, Margriet Oosterveld, Yavuz M. Bilgin, Savita Soechit, Niels W.C.J. van de Donk, Noortje Thielen, Nicole C H P de Graauw, Mark-David Levin, Gert Jan Timmers, Inger S. Nijhof, Kazem Nasserinejad, Alain Kentos, Marjolein van der Klift, Claudia A.M. Stege, Saskia K. Klein, Esther G.M. De Waal, Matthijs H Silbermann, Maaike Sohne, Marie-Christiane Vekemans, Sonja Zweegman, Roel J.W. van Kampen, Nazik Durdu-Rayman
Publikováno v:
Journal of clinical oncology, Vol. 39, no. 25, p. 2758-2767 (2021)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(25), 2758-2767. American Society of Clinical Oncology
Stege, C A M, Nasserinejad, K, van der Spek, E, Bilgin, Y M, Kentos, A, Sohne, M, van Kampen, R J W, Ludwig, I, Thielen, N, Durdu-Rayman, N, de Graauw, N C H P, van de Donk, N W C J, de Waal, E G M, Vekemans, M C, Timmers, G J, van der Klift, M, Soechit, S, Geerts, P A F, Silbermann, M H, Oosterveld, M, Nijhof, I S, Sonneveld, P, Klein, S K, Levin, M D & Zweegman, S 2021, ' Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma : The Hovon 143 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 25, pp. 2758-2767 . https://doi.org/10.1200/JCO.20.03143
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(25), 2758-2767. American Society of Clinical Oncology
Stege, C A M, Nasserinejad, K, van der Spek, E, Bilgin, Y M, Kentos, A, Sohne, M, van Kampen, R J W, Ludwig, I, Thielen, N, Durdu-Rayman, N, de Graauw, N C H P, van de Donk, N W C J, de Waal, E G M, Vekemans, M C, Timmers, G J, van der Klift, M, Soechit, S, Geerts, P A F, Silbermann, M H, Oosterveld, M, Nijhof, I S, Sonneveld, P, Klein, S K, Levin, M D & Zweegman, S 2021, ' Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma : The Hovon 143 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 25, pp. 2758-2767 . https://doi.org/10.1200/JCO.20.03143
PURPOSE Frail patients with newly diagnosed multiple myeloma have an inferior outcome, mainly because of a high discontinuation rate due to toxicity. We designed a phase II trial specifically for frail patients, evaluating the efficacy and tolerabili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd16999f1d8f8fc2bbefd1520cedee3
https://hdl.handle.net/2078.1/261917
https://hdl.handle.net/2078.1/261917
Autor:
Luciana Molinero, Christopher J. Darus, Xiaohua Wu, Johanna Mäenpää, Charles K. Anderson, Nicoletta Colombo, Aikou Okamoto, Giovanni Scambia, Y. García, Fan Wu, Michael A. Bookman, Yvonne G. Lin, Victor Khor, L. Willmott, Jalid Sehouli, Tashanna Myers, Michalis Liontos, Rustem Safin, Michael A. Gold, Cagatay Taskiran, Katina Robison, Austin Miller, Vidya Maiya, Sudarshan K. Sharma, Carol Aghajanian, Sandro Pignata, Jessica Thomes-Pepin, Kathleen N. Moore
Publikováno v:
J Clin Oncol
Journal of Clinical Oncology
Journal of Clinical Oncology
Purpose: to evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC). Methods: this multicent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ea89f9ab83f69d1132450dbd7ec3832
http://hdl.handle.net/10281/327598
http://hdl.handle.net/10281/327598
Autor:
Roch Houot, Emmanuelle Nicolas Virelizier, Jehan Dupuis, Magda Alexis, Virginie De Wilde, Luc-Matthieu Fornecker, Julien Lazarovici, Marc André, Franck Morschhauser, David Sibon, Judith Racapé, Hervé Ghesquières, Anne-Claire Gac, Delphine Pranger, Hannah Moatti, Isabelle Demeestere, Hervé Maisonneuve, Julie Dechene, Adrian Tempescul, René-Olivier Casasnovas, Mohamed Touati
Publikováno v:
Journal of clinical oncology, Vol. 39, no. 29, p. 3251-3260 (2021)
PURPOSE The prospective, randomized AHL2011 trial demonstrated that the use of the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen (ABVD) after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3237911cf6c7b7a7f9de0ae8fd2d84d3
https://hdl.handle.net/2078.1/248868
https://hdl.handle.net/2078.1/248868
Autor:
Cristina Saura, Suzette Delaloge, Sung Bae Kim, Mafalda Oliveira, Yen-Shen Lu, Bin Yao, John Crown, Ming-Shen Dai, Hong-Tai Chang, Thomas Yau, Takaaki Fujii, Nala Investigators, Daniele Fagnani, Maureen E. Trudeau, Ming-Feng Hou, William J. Gradishar, Johanna Mattson, Marketa Palacova, Barbara Haley, Masato Takahashi, Beverly Moy, Yu-Min Yeh, Richard Bryce, Kiana Keyvanjah, Miki Yamaguchi, Shang Wen Chen, Judith Bebchuk, Adam Brufsky, Norikazu Masuda, Michelino De Laurentiis, Yin-Hsun Feng, Johnson Lin, Toshimi Takano, Sara A. Hurvitz, Hans Wildiers, Yoon Sim Yap
Publikováno v:
Scientia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 27
Journal of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 27
Journal of Clinical Oncology
PURPOSE NALA (ClinicalTrials.gov identifier: NCT01808573 ) is a randomized, active-controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), plus capecitabine (N+C) against lapatinib, a reversible dual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::159f30e1fe5fe41093b211fdc40434ed
https://hdl.handle.net/11351/6232
https://hdl.handle.net/11351/6232
Autor:
Shripad Banavali, Sunil Raut, Vikram Gota, Gaurav Narula, Ritu Singh, Ankita Awase, Khushboo Gandhi, Manjunath Nookala Krishnamurthy, Ruta Pandit
Publikováno v:
JCO Global Oncology
PURPOSE Pegylated asparaginase is comparatively safer than native asparaginase in the management of acute lymphoblastic leukemia (ALL). However, the high price and nonavailability in low- and middle-income countries limits its use. In 2014, the first
Autor:
S. Bhide, Eva Segelov, Rebecca Muirhead, Clare Peckitt, John J. Welch, Sheela Rao, Al B. Benson, R. Glynne-Jones, Cathy Eng, Amitesh Roy, Francesco Sclafani, Matthew T. Seymour, John Bridgewater, Mark P Saunders, David Cunningham, Annette Bryant, Dirk Arnold, Peter O'Dwyer, Richard Adams, David Sebag-Montefiore, Marianne Grønlie Guren
Publikováno v:
J Clin Oncol
PURPOSE To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen. PATIENTS AND METHODS Patients who had not received systemic therapy for advanced anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc68869d7b7f5e0c8806cfc0e06aded
https://europepmc.org/articles/PMC7406334/
https://europepmc.org/articles/PMC7406334/
Publikováno v:
JCO Global Oncology
PURPOSE A postmarket evaluation of chemotherapy dosage forms in Ethiopia was conducted to test the accuracy of the chemoPAD, a paper analytical device for drug quality screening. MATERIALS AND METHODS In September of 2018 in Addis Ababa, Ethiopia, 41